A Guide to America’s Seed Fund 2025 Virtual Tour Insights
INNOVATE Act: Reshaping America's Small Business Innovation Landscape
The Economic Cost of Cutting Government Research Funding: a Report
FDA Phasing Out Animal Testing
This roadmap outlines a strategic, stepwise approach for the FDA to reduce animal testing in preclinical safety studies with scientifically validated new approach methodologies (NAMs), such as organ-on-a-chip systems, computational modeling, and advanced in vitro assays.
Federal agencies such as NIH and NSF are critical sources of funding for basic and applied scientific research. This brief describes a new analysis of the macroeconomic costs of cutting federal funding for scientific R&D. The brief finds that budget cuts to public R&D would significantly hurt the economy in the long run, with large negative effects on GDP, investment, and government revenue.
The recently introduced INNOVATE Act (Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence) represents the most significant overhaul of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs in years.
The America’s Seed Fund 2025 Virtual Tour provided valuable insights into navigating the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Here is a cohesive summary of the key takeaways, organized into actionable sections.
The FDA's Commissioner's National Priority Voucher (CNPV) program provides a voucher to drug developers to speed up the review process for investigational new drugs (INDs) that align with U.S. national health priorities.
The Center is expected to reduce the number of animals employed in preclinical research testing and follows FDA's roadmap to phase out animal testing in preclinical safety studies.
NIH Establishes the Nation's First Dedicated Organoids Development Center
EU Inc. Public Consultation
Currently, starting a company in Europe means dealing with 27 different national systems: each country has its own rules, paperwork, and legal requirements (like Germany's GmbH, France's SARL, Netherlands' BV, etc.). This creates barriers for entrepreneurs wanting to operate across Europe. A major EU initiative seeks to create a unified European company structure called "EU Inc." or the "28th-Regime" company form.
Investing in Women's Health
Women's health represents one of the most significant untapped opportunities for global economic growth and human development. Despite comprising nearly 50% of the world's population, women's health has been systematically underinvested, underresearched, and undervalued. This white paper examines the economic imperative for investing in women's health and provides actionable recommendations for stakeholders across sectors.
HHS Positions AI as the Core of Health Innovation
In compliance with Executive Order 14179 ("Removing Barriers to American Leadership in AI"), HHS has recently released a 21-page strategy to integrate AI across healthcare, scientific research, and operations.
Transatlantic Divergence in AI Regulation
Artificial intelligence (AI) has shifted from a niche technology to critical infrastructure for economies, national security, and everyday life. Generative AI, in particular, has exposed regulators to new risks around misinformation, discrimination, surveillance, and systemic dependencies on opaque models. By the end of 2025, the European Union (EU) and the United States (US) have taken sharply different regulatory paths.
